Is APD a promising drug in the treatment of severe osteogenesis imperfecta?
The efficacy of (3-amino-1-hydroxypropylidene)-1,1-biphosphonate (APD) is reported in a severe case of osteogenesis imperfecta (OI). An increased density at the metaphysis level is demonstrated on wrist radiograph. Similar findings have been observed in two other children with OI at various metaphyseal levels (e.g., tibia, femur). To our knowledge, this is the first time the effect of APD in children with severe OI has been reported.
Huaux
J P
JP
Service de Rhumatologie, Cliniques Universitaires U.C.L. de Mont-Godinne et St-Luc, Bruxelles, Belgique.
Lokietek
W
W
D002648:Child; D004164:Diphosphonates / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D010013:Osteogenesis Imperfecta / Q000188:drug therapy*; D000077268:Pamidronate
D004164:Diphosphonates; D000077268:Pamidronate